New York, NY – Ipsos Health is set on a growth pattern. The group is announcing two senior level researchers - David Scowcroft as Senior Vice President and Susan Baxter as Vice President – have joined the ranks. This follows last month’s announcement of 10 newly hired research professionals, and the continued expansion of the team.
“David and Susan bring a combined three decades of marketing and research perspective to our team including extensive experience in both the client and consultancy settings. They will add tremendous value in terms of understanding business issues and using research to inform and shape strategic and tactical implementation” says Fred LaManna, Senior Vice President with Ipsos Health. “It is our goal at Ipsos Health to leverage insights that come from an integrated analysis of the multiple stakeholders who impact the success of bio-pharmaceutical brands. With experts like David and Susan on board, we will continue to deliver our promise.”
David Scowcroft’s responsibilities will encompass leading a team of research professionals and new product development. Scowcroft brings over 15 years of experience to the team, with ten of those years centered on healthcare research. Before joining Ipsos Health, he was a senior researcher at Sanofi and subsequently, he ran the quantitative business of a major market research firm.
Susan Baxter will focus primarily on providing client consultation and senior leadership to one of Ipsos’s research teams. Baxter brings extensive client-side research experience via her 15-year career in the Procter & Gamble organization, with a particular focus on the company’s healthcare and pharmaceutical divisions. Just prior to joining Ipsos, she was principal for an independent research consultancy.
In addition to these senior hires, there were 5 incremental hires in June including Jane Wilson who rejoins as a manager. Wilson had spent ten years at Ipsos previously. Newly arriving research associates include: Brittany Bare, Gina Maggi, Katherine Sharga and Andrew Zoller.
For more information on this news release, please contact:
Senior Vice President
About Ipsos Health
Ipsos Health is a full-service, highly-specialized, custom research agency dedicated to delivering commercially-meaningful market research that positively impacts brand performance for clients in the Pharma, Biotech and Medical Device industries. Our team is a blend of Pharmaceutical market research experts, marketers and client-side brand-builders and market researchers, with offices in over 25 countries. Drawing from a broad range of qualitative and quantitative techniques, Ipsos specializes in researching the motivations, experiences, interactions and influence of stakeholders forming the multi-customer markets which increasingly drive business models in the healthcare industry.
To learn more, visit www.ipsoshealth.com .
Ipsos is a leading global survey-based market research company, owned and managed by research professionals. Ipsos helps interpret, simulate, and anticipate the needs and responses of consumers, customers, and citizens around the world.
Member companies assess market potential and interpret market trends. They develop and build brands. They help clients build long-term relationships with their customers. They test advertising and study audience
responses to various media. They measure public opinion around the globe.
Ipsos member companies offer expertise in advertising, customer loyalty, marketing, media, and public affairs research, as well as forecasting, modeling, and consulting. Ipsos has a full line of custom, syndicated,
omnibus, panel, and online research products and services, guided by industry experts and bolstered by advanced analytics and methodologies. The company was founded in 1975 and has been publicly traded
since 1999. In 2010, Ipsos generated global revenues of €1.140 billion ($1.6 billion U.S.).
Visit www.ipsos-na.com to learn more about Ipsos
offerings and capabilities.
Ipsos, listed on the Eurolist of Euronext – Comp B, is part of SBF 120 and the Mid-100 Index, adheres to the Next Prime segment and is eligible to the Deferred Settlement System. Isin FR0000073298, Reuters ISOS.PA, Bloomberg IPS:FP